Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca
PRNewsWire
·
2026-04-30
·
via The Tech Buzz - Press Releases
Option exercise triggers $25M payment to Pinetree. CAMBRIDGE, Mass., April 29, 2026 /PRNewswire/ -- Pinetree Therapeutics, Inc. ("Pinetree"), a biotechnology company pioneering next-generation targete
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。